Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

Slides:

Advertisements

Similar presentations

August 30, 2009 at CET. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial.

Advertisements

Invasive Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATelet Inhibition and patient Outcomes trial Outcomes in.

Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.

Khawar Kazmi. Thrombosis LipidsInflammation Thrombus Platelets and thrombin Quiescent Plaque Plaque rupture PATHOGENESIS ACUTE CORONARY SYNDROME.

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia Sindromi coronariche acute nei pazienti con fibrillazione.

TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel TRITON-TIMI 38 TRITON-TIMI 38 Elliott M. Antman, MD.

Prasugrel Compared to Clopidogrel in Patients with Acute Coronary Syndromes Undergoing PCI with Stenting: the TRITON - TIMI 38 Stent Analysis Stephen D.

Point of Care Platelet Function Testing – Is There Still Value?

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.

What’s New in Acute Coronary Syndromes? Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 13.

NSTE Acute Coronary Syndromes

VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.

TRITON TIMI-38 STEMI cohort Primary End Point (CV death, MI and stroke at 15 months) Adapted from Montalescot et al. ESC Time (days)

The Effect of Cangrelor and Access Site on Ischemic and Bleeding Events – Insights from CHAMPION PHOENIX J. Antonio Gutierrez, MD, MHS, Robert A. Harrington,

TRITON TIMI-38 STEMI cohort Clopidogrel Under Fire: Is Prasugrel in Primary PCI or Recent MI Superior? Insights From TRITON-TIMI-38 Gilles Montalescot,

Measurement of Antiplatelet Therapeutic Efficacy Bonnie H. Weiner MD MSEC MBA FSCAI FACC FAHA Professor of Medicine Director, Interventional Cardiology.

수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.

Adjunctive Antithrombotic for PCI Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville.

Robert A. Harrington, MD Professor of Medicine

_________________ Caitlin M. Gibson, PharmD, BCPS

Bedside monitoring to adjust antiplatelet therapy for Coronary stenting N Engl J Med Nov 29;367: Prof. Soo-Joong Kim / R3 Yu Ho Lee.

PRAGUE-18 Trial design: Patients with STEMI undergoing primary PCI were randomized to prasugrel (n = 634) versus ticagrelor (n = 596). Results (p = 0.94)

Insight into the Gauging Responsiveness with A VerifyNow Assay - Impact on Thrombosis And Safety (GRAVITS) Trial Peter Berger, MD Director, Center for.

Randomisation before planned PCI with DES (n=2500)

Antiplatelet Therapy For STEMI: The Case for Cangrelor

ARCTIC-INTERRUPTION 2-year- Versus 1year Duration of Dual-Antiplatelet Therapy After DES implantation The randomized ARCTIC-Interruption Study JP Collet.

The Big Antiplatelet Debate Why I Prefer Prasugrel Over Ticagrelor

The ANTARCTIC investigators

Preventing Thrombotic Complications in ACS: State of the Art

Oral Anticoagulation and Preventing Stent Thrombosis

Atrial Fibrillation and PCI

11/12/2018 CYP2C19-Clopidogrel Development of these slides was supported by funding from the IGNITE Network. When using or adapting any of these slides.

Updates in Anticoagulation: What Did We Learn From ESC 2017?

NOACs, AF, and PCI: What Do the Latest Data Suggest?

Achieving Long-Term Protection Post-MI

PAD Patients vs Post-ACS Patients:

Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.

Table. Clinical Efficacy and Safety

Introduction Antiplatelet Agents ADP Receptor Antagonists.

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.

Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.

Antithrombotics and PAD: A New Paradigm in Practice

What Has Been Tried and What Is True?

Tailoring Antiplatelet Therapy in PCI

Antiplatelet Therapy and Secondary Prevention

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

Learning Objectives PLATO Primary Efficacy End Point CV Death, MI, or Stroke.

Treatment Options to Consider

Comparison of US and European Guidelines Oral Antiplatelet Therapy in Primary PCI/STEMI.

The Management of ACS “Updated Perspectives and Goals” Rafid F. Al-Aqeedi FIBMS ( Med ), MRCP (London), DM ( Int.Card.), FACC, FESC Consultant Interventional.

ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.

LATITUDE-TIMI 60 Trial design: Patients hospitalized with AMI on guideline-recommended therapy were randomized in a 1:1 fashion to either losmapimod 7.5.

Duration of Dual Antiplatelet Therapy

Factor Xa Inhibitors in PAD

IMPRESSION Trial design: Patients presenting with acute MI and undergoing an invasive approach, along with ticagrelor loading dose, were randomized to.

Updates in Anticoagulation: Key Sessions at ESC 2017

What oral antiplatelet therapy would you choose?

Elevated Admission Plasma Glucose Following ACS

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Factor Xa Inhibitors in Coronary Artery Disease

Cardiology Fellow X Factor: An ACS Case of Therapeutic Challenges

OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)

Update on the New Antiplatelet Agents:

The Case for Routine CYP2C19 ( Plavix® ) Genetic Testing

INTRO AMI. INTEGRILIN AND. REDUCED DOSE. OF THROMBOLYTIC IN. ACUTE

Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.

ESC Guideline on the Management of STEMI Recommendation for DAPT

Section C: Clinical trial update: Oral antiplatelet therapy

Presentation transcript:

Learning Objectives

Variable Response to Clopidogrel

Platelet Reactivity and Outcomes

Clopidogrel Metabolism

CYP450 Genetic Variants and PK/PD

CYP2C19 and Clinical Outcomes

Clopidogrel Boxed Warning

CYP2C19 and Treatment With Clopidogrel

CURRENT-OASIS 7: Study Design, Flow, and Compliance

CURRENT-OASIS 7: Clopidogrel Double (600 mg  150 mg/d x 7d  75 mg/d) vs Standard Dose (300 mg  75 mg/d)

CURRENT-OASIS 7: Clopidogrel Double- vs Standard-Dose Bleeding PCI Population

Tailoring Clopidogrel Dosing With Platelet Function Monitoring

GRAVITAS Study Design

GRAVITAS Primary End Point: CV Death, MI, Stent Thrombosis

GRAVITAS Pharmacodynamics: Effect of SD vs HD Clopidogrel

PRINCIPLE TIMI 44 PRIMARY EP: Acute Phase

PRINCIPLE TIMI 44 PRIMARY EP: Maintenance Phase

TRITON-TIMI 38 13,608 Patients With ACS and Planned PCI Randomized to Prasugrel (60/10) vs Clopidogrel (300/75)

TRITON-TIMI 38 Bleeding Events: Safety Cohort (N = 13,457)

TRILOGY-ACS Study Design

TRILOGY-ACS: Primary Efficacy End Point to 30 Months (Age < 75 years)

Ticagrelor Pharmacodynamics

Platelet Reactivity: Ticagrelor vs Prasugrel

PLATO Primary Efficacy End Point: CV Death, MI, or Stroke

PLATO: Bleeding

TRA-CER Primary End Point: CV Death, MI, Stroke, Hospitalization for Ischemia, Urgent Revascularization

TRA-CER: Bleeding Outcomes

CHAMPION PHOENIX Study Design

CHAMPION PHOENIX: Primary Efficacy Outcomes at 48 Hours, MITT

CHAMPION PHOENIX: Non-CABG Bleeding at 48 Hours

ESC NSTE-ACS Guidelines

Periprocedural Antithrombotic Medication in Primary PCI

Antiplatelet Therapy in UA/NSTEMI

Antiplatelet Therapy to Support Primary PCI for STEMI

Case 1

Case 2

Case 3

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)